Navigation Links
Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Date:10/4/2007

ST. LOUIS, Oct. 4 /PRNewswire/ -- A study published in the Oct. 1 Journal of Nutrition suggests consumption of soy protein may play a role in reducing the risk of prostate cancer, Solae notes, giving consumers another healthy reason to make soy part of their diet.

The study, "Soy protein isolate increases urinary estrogens and the ratio of 2:16 alpha-hydroxyestrone in men at high risk of prostate cancer," is believed to be the first study investigating the effects of soy protein consumption on estrogen metabolism and prostate cancer in men.

"The intent of the study was to evaluate the effects of consuming soy protein on elimination of estrogen metabolites in the urine of men at a high risk for prostate cancer," said Dr. Mindy Kurzer, lead author of the study and a professor in the Department of Food Science and Nutrition at the University of Minnesota. "After taking biopsies of prostate tissue, androgen receptors were reduced in the prostate, which is consistent with a reduced risk of prostate cancer. In addition, significantly fewer of the men who consumed soy protein progressed to cancer by the end of the six-month study. We are encouraged by the results, but more studies must be performed."

"The results of this study could be beneficial for men who are at risk of prostate cancer," said Dr. Kathryn Greaves, Group Lead, Clinical Nutrition at Solae. "If the results of this study are replicated in future studies, reducing the risk of prostate cancer may be another reason to include soy in your daily diet."

Soy has been documented to potentially improve heart health and aid in sports performance and weight management. For more information on Solae and its products, please visit http://www.solae.com.

About Solae

Solae is the world leader in developing innovative soy-based technology to the food, meat and nutritional products industries. Solae provides solutions that deliver a un
'/>"/>

SOURCE Solae
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... ( www.curemark.com ), a drug research and development company focused ... & Renshaw Annual Global Investment Conference held September 12-15 in ... 5,000 investors and other attendees.   "Curemark was ... present at the conference, which included a full roster of ...
... OmniComm Systems, Inc. (OTC Bulletin Board: ... and services announced that it will be hosting the ... Beach Resort in Fort Lauderdale, Florida from November 03-05, ... from participating Life Science organizations. The informal ambiance provides ...
Cached Medicine Technology:Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe ... consultations with specialists, physical therapy, and injections , ... mid back and/or lower back pain, Healthpointe has ... injections for herniated discs, disc protrusions and other ... , Healthpointe’s team of renowned surgeons are ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of Treating ... now offering free weekly call in teleconferences each ... to reduce symptoms associated with fibromyalgia including chronic ... fog. , To find out more about ... in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... (MGH) researchers have identified a new molecular pathway that ... This early-stage kidney disease affects 100 million people around ... the kidneys filtering structures. Blocking this pathway could ... slow the process of kidney failure. The research ...
... impact on behavior, studies show , , WEDNESDAY, Dec. 19 (HealthDay ... trillion cells, looking for perhaps only one or a handful ... of new studies says. , The research, conducted with rodents ... , could rewrite the textbooks on just how important individual ...
... a way to use a firefly gene to let them ... against some forms of cancer and its serious complication. ... and leukemia, a form of cancer where it is particularly ... prognosis is generally poor. There is now no widely effective ...
... Helping Latino Nonprofits and Families With Cash,Donation. Photo ... Latino with,HIV., WASHINGTON, Dec. 19 The ... This holiday season, MAYA is giving $10,000 to ... the Latino community.,MAYA will also donate cash to ...
... Health Net of California See Big Increases in ... Surveyor from HealthLeaders-InterStudy Reveals ... NASHVILLE, Tenn., Dec. 19 HealthLeaders-InterStudy, the,leading ... managed,care enrollment from January 2007 to July 2007 ...
... volunteer John,Cleland has run four marathons, but the race ... Diagnosed with the disease as a college,undergraduate, Cleland underwent ... punishing rounds of chemotherapy followed. But when,Cleland,s cancer spread ... Then Cleland,s doctor offered one small ray of ...
Cached Medicine News:Health News:Receptor protein appears to be key in breakdown of kidney filtration 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 3Health News:Brain Cells More Powerful Than You Think 2Health News:Brain Cells More Powerful Than You Think 3Health News:Brain Cells More Powerful Than You Think 4Health News:Firefly genes allow testing of new therapy against lymphoma 2Health News:Firefly genes allow testing of new therapy against lymphoma 3Health News:HIV/AIDS Rate Increases in DC Area Latino Population, Community Lacks Resources 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 3Health News:New Book Looks at Clinical Research from the Patient's Point of View 2Health News:New Book Looks at Clinical Research from the Patient's Point of View 3
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: